ANPA-0073 is under clinical development by Structure Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANPA-0073’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Structure Therapeutics overview
Structure Therapeutics is a health tech company that provides life-changing medicines for patients using advanced computational and structure-based technology. Structure Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of ANPA-0073’s drug-specific PTSR and LoA scores, buy the report here.